New York-based startup Kaia Health is tackling musculoskeletal (MSK) conditions and chronic obstructive pulmonary disease (COPD). In late April, the company announced it had raised a $75 million in Series C financing round to expand clinical capabilities and transform treatment for the conditions in the U.S. and Europe.
Kaia Health uses machine learning to deliver individualized app-based tasks to help patients control and self-manage their condition from home with real-time exercise feedback. The company said in a news release that it works with medical experts to create accessible, evidence-based treatments for a range of conditions, including back pain, COPD and osteoarthritis.
Kaia Health has raised more than $125 million from investors, including Optum Ventures, Eurazeo, 3VC, Balderton Capital, Heartcore Capital, Symphony Ventures (investment vehicle of golf pro and four-time Major winner Rory McIlroy) and A-Round Capital. The company recently launched Kaia Gateway and Premium Partners, a new MSK care solution for employers and health plans.
“Kaia Health is providing a proven MSK and COPD solution combining computer vision and human care to achieve better outcomes,” said Kaia president & CEO Konstantin Mehl in the release. “For U.S. patients, Kaia Gateway delivers better care with more sophisticated triage plus medical professionals who can help patients access the best care within the Kaia Health ecosystem.”